Literature DB >> 10632831

The cost-effectiveness of different management strategies for patients on chronic warfarin therapy.

J E Lafata1, S A Martin, S Kaatz, R E Ward.   

Abstract

OBJECTIVE: To examine the cost-effectiveness of moving from usual care to more organized management strategies for patients on chronic warfarin therapy.
DESIGN: Using information available in the scientific literature, supplemented with data from a large health system and, when necessary, expert opinion, we constructed a 5-year Markov model to evaluate the health and economic outcomes associated with each of three different anticoagulation management approaches: usual care, anticoagulation clinic testing with a capillary monitor, and patient self-testing with a capillary monitor. PATIENTS: Three hypothetical cohorts of patients beginning long-term warfarin therapy were used to generate model results. MAIN
RESULTS: Model results indicated that moving from usual care to anticoagulation clinic testing would result in a total of 1.7 thromboembolic events and 2.0 hemorrhagic events avoided per 100 patients over 5 years. Another 4.0 thromboembolic events and 0.8 hemorrhagic events would be avoided by moving to patient self-testing. When direct medical care costs and those incurred by patients and their caregivers in receiving care were considered, patient self-testing was the most cost-effective alternative, resulting in an overall cost saving.
CONCLUSIONS: Results illustrate the potential health and economic benefits of organized care management approaches and capillary monitors in the management of patients receiving warfarin therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632831      PMCID: PMC1495325          DOI: 10.1046/j.1525-1497.2000.01239.x

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  35 in total

1.  Factors predicting survival, changes in activity limitations, and disability in a geriatric post-stroke population.

Authors:  M S Dighe; R R Aparasu; H M Rappaport
Journal:  Gerontologist       Date:  1997-08

2.  Prevalence of stroke and stroke-related disability. Estimates from the Auckland stroke studies.

Authors:  R Bonita; N Solomon; J B Broad
Journal:  Stroke       Date:  1997-10       Impact factor: 7.914

3.  Is the EuroQol a valid measure of health-related quality of life after stroke?

Authors:  P J Dorman; F Waddell; J Slattery; M Dennis; P Sandercock
Journal:  Stroke       Date:  1997-10       Impact factor: 7.914

4.  A long-term follow-up of stroke patients.

Authors:  P R Wilkinson; C D Wolfe; F G Warburton; A G Rudd; R S Howard; R W Ross-Russell; R R Beech
Journal:  Stroke       Date:  1997-03       Impact factor: 7.914

5.  Practicability of patient self-testing of oral anticoagulant therapy by the international normalized ratio (INR) using a portable whole blood monitor. A pilot investigation.

Authors:  J M Hasenkam; L Knudsen; H H Kimose; H Grønnesby; J Attermann; N T Andersen; H K Pilegaard
Journal:  Thromb Res       Date:  1997-01-01       Impact factor: 3.944

6.  Outcome following stroke.

Authors:  A Tennant; J M Geddes; J Fear; M Hillman; M A Chamberlain
Journal:  Disabil Rehabil       Date:  1997-07       Impact factor: 3.033

7.  Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation.

Authors:  T B Seto; D A Taira; J Tsevat; W J Manning
Journal:  J Am Coll Cardiol       Date:  1997-01       Impact factor: 24.094

8.  Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

Authors:  P Petersen; G Boysen; J Godtfredsen; E D Andersen; B Andersen
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

9.  Cost effectiveness of monitoring warfarin therapy using standard versus capillary prothrombin times.

Authors:  J E Ansell; A K Hamke; A Holden; N Knapic
Journal:  Am J Clin Pathol       Date:  1989-05       Impact factor: 2.493

10.  Warfarin for dilated cardiomyopathy: a bloody tough pill to swallow?

Authors:  J Tsevat; M H Eckman; R A McNutt; S G Pauker
Journal:  Med Decis Making       Date:  1989 Jul-Sep       Impact factor: 2.583

View more
  24 in total

Review 1.  Accounting for noncompliance in pharmacoeconomic evaluations.

Authors:  D A Hughes; A Bagust; A Haycox; T Walley
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  The best of JGIM.

Authors:  Eric B Bass
Journal:  J Gen Intern Med       Date:  2002-12       Impact factor: 5.128

3.  How Much Time Do Patients Spend on Outpatient Visits?: The American Time Use Survey.

Authors:  Louise B Russell; Yoko Ibuka; Deborah Carr
Journal:  Patient       Date:  2008-07-01       Impact factor: 3.883

4.  Reorganisation of an anticoagulation clinic using a telemedicine system: description of the model and preliminary results.

Authors:  Sophie Testa; Adriano Alatri; Oriana Paoletti; Giampietro Morstabilini; Maria Anunzia Medagliani; Nadia Denti; Emanuela Martellenghi
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

5.  Anticoagulation for stroke prevention: high effectiveness, more cost benefit?

Authors:  Eduard Shantsila; Timothy Watson; Gregory Y H Lip
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

6.  A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.

Authors:  Lisa M Meckley; James M Gudgeon; Jeffrey L Anderson; Marc S Williams; David L Veenstra
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Massachusetts Health Reform Cost Less and Was More Effective for Uninsured Individuals With Venous Thromboembolism: A Cost-Effectiveness Analysis.

Authors:  Alok Kapoor; Nicholas Shaffer; Amresh Hanchate; Mark Roberts; Kenneth Smith
Journal:  Med Care       Date:  2016-05       Impact factor: 2.983

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

9.  Patient time requirements for anticoagulation therapy with warfarin.

Authors:  Daniel E Jonas; Betsy Bryant Shilliday; W Russell Laundon; Michael Pignone
Journal:  Med Decis Making       Date:  2009-09-22       Impact factor: 2.583

Review 10.  Polymorphism induced sensitivity to warfarin: a review of the literature.

Authors:  Michael P Palkimas; Hillary M Skinner; Pritesh J Gandhi; Alice J Gardner
Journal:  J Thromb Thrombolysis       Date:  2003-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.